Anavex Life Sciences (STU:12X1) Forward Dividend Yield % : 0.00% (As of May. 24, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Anavex Life Sciences Forward Dividend Yield %?

As of today (2024-05-24), the Forward Annual Dividend Yield of Anavex Life Sciences is 0.00%.

As of today (2024-05-24), the Trailing Annual Dividend Yield of Anavex Life Sciences is 0.00%.

STU:12X1's Forward Dividend Yield % is not ranked ^*
in the Biotechnology industry.
Industry Median: 1.6
* Ranked among companies with meaningful Forward Dividend Yield % only.

Anavex Life Sciences's Dividends per Share for the three months ended in Mar. 2024 was €0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Anavex Life Sciences's Forward Dividend Yield %

For the Biotechnology subindustry, Anavex Life Sciences's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anavex Life Sciences's Forward Dividend Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anavex Life Sciences's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Anavex Life Sciences's Forward Dividend Yield % falls into.

Anavex Life Sciences Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.

Anavex Life Sciences (STU:12X1) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.

Anavex Life Sciences Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Anavex Life Sciences's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Anavex Life Sciences (STU:12X1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anavex Life Sciences Corp (STU:12X1) » Definitions » Forward Dividend Yield %

Comparable Companies

Traded in Other Exchanges

AVXL:USA 12X1:Germany

Address

630 5th Avenue, 20th Floor, New York, NY, USA, 10111

Website

https://www.anavex.com

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its necessary compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder. The company's operating segment is into developing novel therapies for the management of CNS diseases.

Anavex Life Sciences (STU:12X1) Headlines

No Headlines